{"id":65201,"date":"2026-05-13T22:25:12","date_gmt":"2026-05-13T14:25:12","guid":{"rendered":"https:\/\/flcube.com\/?p=65201"},"modified":"2026-05-13T22:25:13","modified_gmt":"2026-05-13T14:25:13","slug":"boehringer-ingelheim-secures-global-rights-to-immunitas-first-in-class-antibody-program-for-chronic-inflammatory-diseases-in-e407-5m-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65201","title":{"rendered":"Boehringer Ingelheim Secures Global Rights to Immunitas&#8217; First-in-Class Antibody Program for Chronic Inflammatory Diseases in \u20ac407.5M Deal"},"content":{"rendered":"\n<p><strong>Boehringer Ingelheim (&#8220;BI&#8221;)<\/strong> and <strong>Immunitas Therapeutics<\/strong> announced on May 12, 2026, a <strong>global licensing agreement<\/strong> for a <strong>preclinical first-in-class antibody program<\/strong> targeting <strong>chronic inflammatory and autoimmune diseases<\/strong>, with potential milestone payments totaling <strong>\u20ac407.5 million<\/strong> (USD 478.24 million).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Boehringer Ingelheim + Immunitas Therapeutics<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Preclinical first-in-class antibody program<\/td><\/tr><tr><td><strong>Therapeutic Area<\/strong><\/td><td>Chronic inflammatory and autoimmune diseases<\/td><\/tr><tr><td><strong>Rights Granted<\/strong><\/td><td>Worldwide development, manufacturing, and commercialization<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>Undisclosed amount<\/td><\/tr><tr><td><strong>Total Milestone Value<\/strong><\/td><td>Up to \u20ac407.5 million (USD 478.24 million)<\/td><\/tr><tr><td><strong>Additional Consideration<\/strong><\/td><td>Tiered royalties on future sales<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>May 12, 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-novel-therapeutic-approach\">Novel Therapeutic Approach<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-target-differentiation-strategy\">Target Differentiation Strategy<\/h3>\n\n\n\n<p>The licensed program represents a <strong>paradigm shift<\/strong> from conventional anti-inflammatory approaches:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Conventional Therapies<\/th><th>Immunitas Program<\/th><\/tr><\/thead><tbody><tr><td>Block individual inflammatory signals (cytokines, receptors)<\/td><td><strong>Selectively targets pathogenic cells<\/strong> driving chronic inflammation<\/td><\/tr><tr><td>Systemic immunosuppression<\/td><td><strong>Localized action<\/strong> at sites of inflammation<\/td><\/tr><tr><td>Transient symptom relief<\/td><td>Potential for <strong>sustained disease control<\/strong><\/td><\/tr><tr><td>Broad immune modulation<\/td><td><strong>Precision targeting<\/strong> of disease-causing cell subsets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-clinical-rationale\">Clinical Rationale<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet medical need<\/strong>: Addresses patients who <strong>do not respond adequately to current therapies<\/strong><\/li>\n\n\n\n<li><strong>Disease modification<\/strong>: Aims to achieve <strong>deeper and more durable benefit<\/strong> across multiple inflammatory conditions<\/li>\n\n\n\n<li><strong>Pathogenic cell targeting<\/strong>: Focuses on <strong>cells localized at inflammation sites<\/strong> rather than circulating mediators<\/li>\n\n\n\n<li><strong>Broad applicability<\/strong>: Platform approach potentially effective across <strong>range of inflammatory conditions<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-portfolio-impact\">Strategic Rationale &amp; Portfolio Impact<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-boehringer-ingelheim\">For Boehringer Ingelheim<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immunology expansion<\/strong>: Strengthens BI&#8217;s position in high-value inflammatory disease market<\/li>\n\n\n\n<li><strong>First-in-class opportunity<\/strong>: Access to novel mechanism with potential blockbuster profile<\/li>\n\n\n\n<li><strong>Global rights<\/strong>: Complete worldwide control enables optimal development and commercialization strategy<\/li>\n\n\n\n<li><strong>Pipeline diversification<\/strong>: Adds innovative biologic to complement existing small molecule portfolio<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-immunitas-therapeutics\">For Immunitas Therapeutics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capital optimization<\/strong>: Significant non-dilutive funding through milestones and royalties<\/li>\n\n\n\n<li><strong>Development de-risking<\/strong>: Leverages BI&#8217;s global development expertise and infrastructure<\/li>\n\n\n\n<li><strong>Commercial validation<\/strong>: Partnership with established pharmaceutical leader validates platform technology<\/li>\n\n\n\n<li><strong>Focus preservation<\/strong>: Enables Immunitas to concentrate resources on other pipeline assets<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Inflammatory disease market<\/strong>: Global autoimmune and inflammatory therapeutics market projected to reach <strong>$185 billion by 2030<\/strong><\/li>\n\n\n\n<li><strong>Treatment resistance<\/strong>: Up to <strong>40% of patients<\/strong> fail to achieve adequate response with current standard-of-care therapies<\/li>\n\n\n\n<li><strong>Biologics evolution<\/strong>: Next-generation approaches focus on <strong>cellular targets<\/strong> rather than cytokine blockade<\/li>\n\n\n\n<li><strong>Platform potential<\/strong>: Success could validate Immunitas&#8217; targeting approach for application across multiple indications<\/li>\n<\/ul>\n\n\n\n<p>The transaction reflects broader industry trends toward <strong>precision immunology<\/strong>, where selective targeting of pathogenic cell populations offers potential for improved efficacy and safety compared to broad immunosuppression.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding development timelines, regulatory approvals, and commercial potential. Actual results may differ due to risks including preclinical-to-clinical translation, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boehringer Ingelheim (&#8220;BI&#8221;) and Immunitas Therapeutics announced on May 12, 2026, a global licensing agreement&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[65,390],"class_list":["post-65201","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-auto-immune","tag-boehringer-ingelheim"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Boehringer Ingelheim Secures Global Rights to Immunitas&#039; First-in-Class Antibody Program for Chronic Inflammatory Diseases in \u20ac407.5M Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Boehringer Ingelheim (&quot;BI&quot;) and Immunitas Therapeutics announced on May 12, 2026, a global licensing agreement for a preclinical first-in-class antibody program targeting chronic inflammatory and autoimmune diseases, with potential milestone payments totaling \u20ac407.5 million (USD 478.24 million).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65201\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boehringer Ingelheim Secures Global Rights to Immunitas&#039; First-in-Class Antibody Program for Chronic Inflammatory Diseases in \u20ac407.5M Deal\" \/>\n<meta property=\"og:description\" content=\"Boehringer Ingelheim (&quot;BI&quot;) and Immunitas Therapeutics announced on May 12, 2026, a global licensing agreement for a preclinical first-in-class antibody program targeting chronic inflammatory and autoimmune diseases, with potential milestone payments totaling \u20ac407.5 million (USD 478.24 million).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65201\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-13T14:25:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-13T14:25:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65201#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65201\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boehringer Ingelheim Secures Global Rights to Immunitas&#8217; First-in-Class Antibody Program for Chronic Inflammatory Diseases in \u20ac407.5M Deal\",\"datePublished\":\"2026-05-13T14:25:12+00:00\",\"dateModified\":\"2026-05-13T14:25:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65201\"},\"wordCount\":427,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Boehringer Ingelheim\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65201#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65201\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65201\",\"name\":\"Boehringer Ingelheim Secures Global Rights to Immunitas' First-in-Class Antibody Program for Chronic Inflammatory Diseases in \u20ac407.5M Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-13T14:25:12+00:00\",\"dateModified\":\"2026-05-13T14:25:13+00:00\",\"description\":\"Boehringer Ingelheim (\\\"BI\\\") and Immunitas Therapeutics announced on May 12, 2026, a global licensing agreement for a preclinical first-in-class antibody program targeting chronic inflammatory and autoimmune diseases, with potential milestone payments totaling \u20ac407.5 million (USD 478.24 million).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65201#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65201\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65201#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boehringer Ingelheim Secures Global Rights to Immunitas&#8217; First-in-Class Antibody Program for Chronic Inflammatory Diseases in \u20ac407.5M Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boehringer Ingelheim Secures Global Rights to Immunitas' First-in-Class Antibody Program for Chronic Inflammatory Diseases in \u20ac407.5M Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Boehringer Ingelheim (\"BI\") and Immunitas Therapeutics announced on May 12, 2026, a global licensing agreement for a preclinical first-in-class antibody program targeting chronic inflammatory and autoimmune diseases, with potential milestone payments totaling \u20ac407.5 million (USD 478.24 million).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65201","og_locale":"en_US","og_type":"article","og_title":"Boehringer Ingelheim Secures Global Rights to Immunitas' First-in-Class Antibody Program for Chronic Inflammatory Diseases in \u20ac407.5M Deal","og_description":"Boehringer Ingelheim (\"BI\") and Immunitas Therapeutics announced on May 12, 2026, a global licensing agreement for a preclinical first-in-class antibody program targeting chronic inflammatory and autoimmune diseases, with potential milestone payments totaling \u20ac407.5 million (USD 478.24 million).","og_url":"https:\/\/flcube.com\/?p=65201","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-13T14:25:12+00:00","article_modified_time":"2026-05-13T14:25:13+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65201#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65201"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boehringer Ingelheim Secures Global Rights to Immunitas&#8217; First-in-Class Antibody Program for Chronic Inflammatory Diseases in \u20ac407.5M Deal","datePublished":"2026-05-13T14:25:12+00:00","dateModified":"2026-05-13T14:25:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65201"},"wordCount":427,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Boehringer Ingelheim"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65201#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65201","url":"https:\/\/flcube.com\/?p=65201","name":"Boehringer Ingelheim Secures Global Rights to Immunitas' First-in-Class Antibody Program for Chronic Inflammatory Diseases in \u20ac407.5M Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-13T14:25:12+00:00","dateModified":"2026-05-13T14:25:13+00:00","description":"Boehringer Ingelheim (\"BI\") and Immunitas Therapeutics announced on May 12, 2026, a global licensing agreement for a preclinical first-in-class antibody program targeting chronic inflammatory and autoimmune diseases, with potential milestone payments totaling \u20ac407.5 million (USD 478.24 million).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65201#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65201"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65201#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boehringer Ingelheim Secures Global Rights to Immunitas&#8217; First-in-Class Antibody Program for Chronic Inflammatory Diseases in \u20ac407.5M Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65201","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65201"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65201\/revisions"}],"predecessor-version":[{"id":65203,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65201\/revisions\/65203"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65201"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65201"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65201"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}